Mediwound announces closing of public offering of ordinary shares

Yavne, israel, march 10, 2022 (globe newswire) -- mediwound ltd. (nasdaq: mdwd) (“mediwound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, today announced that on march 7, 2022 it closed its previously announced underwritten public offering of 5,208,333 ordinary shares at a public offering price of $1.92 per share. the gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $10 million. mediwound also granted the underwriters a 30-day option to purchase up to an additional 781,249 ordinary shares at the public offering price, less underwriting discounts and commissions.
MDWD Ratings Summary
MDWD Quant Ranking